Stock Research for AGIO

AGIO

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AGIO Stock Chart & Research Data

The AGIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AGIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AGIO Due diligence Resources & Stock Charts

The AGIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AGIO Detailed Price Forecast - CNN Money CNN View AGIO Detailed Summary - Google Finance
Yahoo View AGIO Detailed Summary - Yahoo! Finance Zacks View AGIO Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AGIO Trends & Analysis - Trade-Ideas Barrons View AGIO Major Holders - Barrons
NASDAQ View AGIO Call Transcripts - NASDAQ Seeking View AGIO Breaking News & Analysis - Seeking Alpha
Spotlight View AGIO Annual Report - CompanySpotlight.com OTC Report View AGIO OTC Short Report - OTCShortReport.com
TradeKing View AGIO Fundamentals - TradeKing Charts View AGIO SEC Filings - Bar Chart
WSJ View Historical Prices for AGIO - The WSJ Morningstar View Performance/Total Return for AGIO - Morningstar
MarketWatch View the Analyst Estimates for AGIO - MarketWatch CNBC View the Earnings History for AGIO - CNBC
StockMarketWatch View the AGIO Earnings - StockMarketWatch MacroAxis View AGIO Buy or Sell Recommendations - MacroAxis
Bullish View the AGIO Bullish Patterns - American Bulls Short Pains View AGIO Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AGIO Stock Mentions - StockTwits PennyStocks View AGIO Stock Mentions - PennyStockTweets
Twitter View AGIO Stock Mentions - Twitter Invest Hub View AGIO Investment Forum News - Investor Hub
Yahoo View AGIO Stock Mentions - Yahoo! Message Board Seeking Alpha View AGIO Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AGIO - SECform4.com Insider Cow View Insider Transactions for AGIO - Insider Cow
CNBC View AGIO Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AGIO - OTC Markets
Yahoo View Insider Transactions for AGIO - Yahoo! Finance NASDAQ View Institutional Holdings for AGIO - NASDAQ


Stock Charts

FinViz View AGIO Stock Insight & Charts - FinViz.com StockCharts View AGIO Investment Charts - StockCharts.com
BarChart View AGIO Stock Overview & Charts - BarChart Trading View View AGIO User Generated Charts - Trading View




Latest Financial News for AGIO


What Are Analysts Saying About Agios Pharmaceuticals, Inc.'s (NASDAQ:AGIO) Earnings Outlook?
Posted on Thursday April 11, 2019

Agios Pharmaceuticals, Inc.'s (NASDAQ:AGIO) released its most recent earnings update in December 2018, which showed that losses became smaller relative to the prior year's level - great news for inve...


See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
Posted on Tuesday April 09, 2019

Agios Pharmaceuticals Inc NASDAQ/NGS:AGIOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is high for AGIO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AGIO. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $942 million over the last one-month into ETFs that hold AGIO are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.


Agios Announces New Commercial Leadership Structure
Posted on Tuesday April 02, 2019

Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced two newly created commercial leadership roles to support the commercialization of the company’s medicines in the United States and Europe. Darrin Miles, who has been with the company since 2015, most recently as vice president, oncology program leadership, has been promoted to senior vice president, U.S. commercial and global marketing and will be responsible for leading the commercial organization in the U.S. and driving coordinated marketing efforts worldwide for all of Agios products and development candidates.


AVEO Reports Positive Results on Leukemia Drug, Shares Up
Posted on Tuesday April 02, 2019

AVEO Oncology (AVEO) reports positive results from phase Ib study of ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.